Disclosed CapitolDisclosedCapitol
Home
Plans
Chad AI
API
Sign InGet Pro

Never Miss a Trade

Get weekly trade alerts free.

Explore

  • Politician Trades
  • Politicians
  • Executive Branch
  • Companies
  • All Stocks A–Z
  • Leaderboard
  • Compare Politicians
  • Committee Portfolios
  • Chad AI

Money & Policy

  • Government Contracts
  • Lobbying
  • Legislation
  • Campaign Finance
  • Institutional (13F)
  • Whale Watch (13D)

Markets

  • Markets Overview
  • Top Companies
  • Insider Trends
  • Economic Indicators
  • Live News

Resources

  • API Access
  • Developers
  • Data Export
  • Glossary
  • Methodology
  • Data Sources
  • How It Works

Company

  • About Us
  • Press
  • FAQ
  • Pricing
  • vs. Capitol Trades
  • Contact
  • Watchlist

Legal

  • Editorial Standards
  • Corrections
  • Disclaimers
  • Privacy
  • Terms
© 2026 Disclosed Capitol. All rights reserved.
TermsPrivacyDisclaimer
HomeTrades
Chad
WatchlistAccount

ELAN

Healthcare
Elanco Animal Health Incorporated · Drug Manufacturers - Specialty & Generic
Trades
65
Politicians
0
Buys
24
Sells
28
Trades
65
Politicians
0
Buys
24
Sells
28
ELANvs S&P 500 (normalized)
|to
No price data available
ELAN S&P 500 Buy Sell
Range
PoliticianActionDescriptionAmountTradedFiled
Ro KhannaD
SellELANCO ANIMAL HEALTH INCORPO$1K - $15KAug 4, 2026Sep 1, 2026
Valerie HoyleD
SellElanco Animal Health Incorpo$1K - $15KSep 23, 2025Oct 10, 2025
Ro KhannaD
SellELANCO ANIMAL HEALTH INCORPO$1K - $15KSep 22, 2025Oct 3, 2025
Ro KhannaD
SellELANCO ANIMAL HEALTH INCORPO$1K - $15KJun 10, 2025Jul 9, 2025
Ro KhannaD
SellELANCO ANIMAL HEALTH INCORPO$1K - $15KMay 12, 2025Jun 10, 2025
Ro KhannaD
SellELANCO ANIMAL HEALTH INCORPO$1K - $15KMay 8, 2025Jun 10, 2025
Ro KhannaD
BuyELANCO ANIMAL HEALTH INCORPO$1K - $15KApr 10, 2025May 12, 2025
Ro KhannaD
SellELANCO ANIMAL HEALTH INCORPO$1K - $15KJan 17, 2025Feb 6, 2025
Ro KhannaD
BuyELANCO ANIMAL HEALTH INCORPO$1K - $15KJan 17, 2025Feb 6, 2025
Ro KhannaD
BuyELANCO ANIMAL HEALTH INCORPO$1K - $15KDec 16, 2024Jan 7, 2025
65 trades
…

Elanco Animal Health Incorporated (ELAN) Congressional Stock Trades

This page tracks congressional stock trading activity in Elanco Animal Health Incorporated (ELAN) in the Healthcare sector. Disclosed Capitol has indexed 65 disclosed congressional trades involving ELAN. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.

As of September 2026 — Disclosed Capitol has tracked 65 disclosed congressional trades in Elanco Animal Health Incorporated (ELAN) — 28:24 sell-heavy ratio — led by Ro Khanna (D).

Which members of Congress trade Elanco Animal Health Incorporated?

  • Ro Khanna (D) — 34 disclosed trades in ELAN
  • Michael McCaul (R) — 13 disclosed trades in ELAN
  • Alan S. Lowenthal (D) — 7 disclosed trades in ELAN
  • Susie Lee (D) — 5 disclosed trades in ELAN
  • Daniel Goldman (D) — 2 disclosed trades in ELAN

Recent ELAN congressional trades

DatePoliticianPartyActionAmount
Aug 4, 2026Ro KhannaDSell$1,001 - $15,000
Sep 23, 2025Valerie HoyleDSale$1,001 - $15,000
Sep 22, 2025Ro KhannaDSale$1,001 - $15,000
Jun 10, 2025Ro KhannaDSale$1,001 - $15,000
May 12, 2025Ro KhannaDSale$1,001 - $15,000
May 8, 2025Ro KhannaDSale$1,001 - $15,000
Apr 10, 2025Ro KhannaDPurchase$1,001 - $15,000
Jan 17, 2025Ro KhannaDSale$1,001 - $15,000
Jan 17, 2025Ro KhannaDPurchase$1,001 - $15,000
Dec 16, 2024Ro KhannaDPurchase$1,001 - $15,000

Buy vs. sell ratio & volume

Across the 65 disclosed congressional trades in Elanco Animal Health Incorporated (ELAN), members of Congress have reported 24 buys and 28 sells. The average 30-day alpha vs. the S&P 500 is 1.63%.

Elanco Animal Health Incorporated financial snapshot (FY2025)

For fiscal year 2025, Elanco Animal Health Incorporated reported revenue of $4.71B and net income of -$232.0M, per SEC filings.

Revenue
$4.71B
Gross profit
$2.59B
Net income
-$232.0M
Diluted EPS
$-0.47
Gross margin
55.0%
Net margin
-4.9%
Free cash flow
$284.0M

Most recent reported quarter: Q2 FY2026 — revenue $2.74B, net income $111.0M.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.